dr. otterson on when to start immunotherapy in nsclc
Published 4 years ago • 127 plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
0:55
dr. otterson on the utility of immunotherapy in nsclc
-
5:58
how long to continue immunotherapy
-
1:28
dr. otterson on targetable biomarkers in lung cancer
-
5:25
immunotherapy in lung cancer
-
1:11
dr. lopes on the rationale to stop immunotherapy after 2 years in lung cancer
-
2:04
dr. kelly on challenges with starting immunotherapy in lung cancer
-
1:25
dr. brahmer on chemoimmunotherapy in patients with nsclc
-
6:06
stage iii nsclc: when to start durvalumab
-
1:22
dr. bauml on the use of immunotherapy in oligometastatic nsclc
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
1:33
dr. anne chiang on molecular testing in lung cancer treatment planning
-
59:37
marking new milestones with immunotherapy in locally advanced and early lung cancer
-
2:18
dr. wakelee on first trial to combine antiangiogenesis agents with immunotherapy in nsclc
-
1:55
dr. gandara on the impact of immunotherapy on the tumor microenvironment in lung cancer
-
1:05
dr. chiang on unanswered questions with immunotherapy in nsclc
-
1:08
dr. donington on the role of neoadjuvant immunotherapy in stage ii nsclc
-
0:48
immunotherapy for patients with small-cell lung cancer
-
1:17
dr. chaft on investigational neoadjuvant immunotherapy approaches in nsclc
-
1:15
dr. brahmer on immunotherapy beyond pd-1/l1 in nsclc